Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_assertion type Assertion NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_head.
- NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_assertion description "[Notwithstanding the convincing rationale for angiotensin II blockade as a treatment modality, the incidence of diabetes-related end stage renal disease has increased steadily despite widespread use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_provenance.
- NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_assertion evidence source_evidence_literature NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_provenance.
- NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_assertion SIO_000772 21067505 NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_provenance.
- NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_assertion wasDerivedFrom befree-20150227 NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_provenance.
- NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_assertion wasGeneratedBy ECO_0000203 NP348996.RADfWhH61_vpmuk1dQg0OHo8YyNvA3MUxwtELlD0MeCXg130_provenance.